N-Acylated Glucosamine Derivatives for Bone Micro-Architecture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing bone mineral density (BMD) and treating osteoporosis are limited, as they do not effectively improve bone micro-architecture or connectivity, and dual energy X-ray absorptiometry (DXA) technology does not assess bone quality, leading to incomplete fracture risk prediction and inadequate treatment of fractures.
Innovation Solution
Administration of N-acylated glucosamine derivatives, such as N-butyryl-D-glucosamine, to mammals to increase BMD, improve bone micro-architecture, and enhance fracture healing, which modulates growth factors like IGF-1 and reduces the risk of fractures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bi-phosphonates are used to increase BMD, then bone mineral density is improved, but bone micro-architecture and connectivity are not improved
Solution Approach 1:
The patent changes the chemical parameter from bi-phosphonates to glucosamine-based compounds, which have different mechanisms of action. Glucosamine derivatives not only increase BMD but also improve bone micro-architecture and connectivity by stimulating osteoblast activity and collagen synthesis, thereby resolving the contradiction between quantity and structural quality.
Solution Approach 2:
The invention uses composite glucosamine derivatives with specific acyl groups (such as N-butyryl-D-glucosamine) that combine multiple functional properties. These compounds simultaneously enhance bone mineral density and improve micro-architectural quality, addressing both aspects of the contradiction through a multi-functional agent.
2Measurement precision
If DXA technology is used to measure BMD, then standardized BMD assessment is achieved, but bone quality and micro-architecture are not assessed
Solution Approach 1:
The patent introduces glucosamine-based compounds as an intermediary treatment that addresses both BMD and bone quality. While DXA continues to measure BMD, the treatment itself targets micro-architecture improvements, effectively bridging the information gap by treating both parameters simultaneously rather than relying solely on measurement technology.
3Quantity of substance
If N-acylated glucosamines are administered, then bone mineral density is increased and bone micro-architecture is improved, but the mechanism involves complex modulation of growth factors
Solution Approach 1:
The glucosamine derivatives activate the body's own growth factor systems (IGF-1, TGF-β) to promote bone formation. Rather than directly forcing bone growth through a simple mechanism, the compound enables the body's natural regulatory systems to self-correct bone density and architecture, managing complexity through biological self-regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of N-acylated glucosamine derivatives effectively increases BMD, improves bone micro-architecture, and accelerates fracture healing, providing a comprehensive approach to treating osteoporosis and fractures by enhancing bone connectivity and reducing the risk of fragility fractures.
Implementation Method 1
The use of N-acylated glucosamine derivatives effectively increases BMD, improves bone micro-architecture, and accelerates fracture healing, providing a comprehensive approach to treating osteoporosis and fractures by enhancing bone connectivity and reducing the risk of fragility fractures.
Data Source
AI summary
A method of treating a mammal for a purpose selected from the group consisting of (a) increasing bone mineral density (BMD), (b) treating low BMD, (c) preventing and treatment of low impact fractures, (d) treatment of high impact fractures; (e) treating osteoporosis; (f) modulating a growth factor that influences bone metabolism; and (g) improving bone micro-architecture or connectivity of bone; the method comprising administering to the mammal an effective amount of a N-acylated-2-glucosamine derivative of the general formula (I):wherein R is an alkyl radical of the general formula CnH2n+1 and n is selected from 2-12; or pharmaceutically-acceptable salts, esters and glucosides thereof; or pharmaceutically-acceptable compositions thereof.